Year All 2026 2025 2024 October 29, 2026 Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 Read More October 28, 2026 Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set Read More October 15, 2026 Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference Read More October 13, 2026 Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference Read More October 12, 2026 Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 Read More September 28, 2026 U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Read More September 9, 2026 Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer Read More September 2, 2026 Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences Read More August 31, 2026 Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Read More August 5, 2026 Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Read More
October 29, 2026 Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026 Read More
October 28, 2026 Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set Read More
October 15, 2026 Palvella Therapeutics to Present Phase 3 SELVA and Phase 2 TOIVA Results, Along With New Pediatric Analyses, at 2026 PeDRA Annual Conference Read More
October 13, 2026 Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference Read More
October 12, 2026 Palvella Therapeutics Announces Three Poster Presentations Highlighting New Data in Microcystic Lymphatic Malformations and DSAP at Fall Clinical Dermatology 2026 Read More
September 28, 2026 U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Read More
September 9, 2026 Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer Read More
September 2, 2026 Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences Read More
August 31, 2026 Palvella Therapeutics Completes Rolling Submission of New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations Read More
August 5, 2026 Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Read More
